Evidence mapPaperPMID 34211366Full record

ArticleFrontiers in neuroscience2021

[

Rommani Mondal, Anthony-David Tawatao Campoy, Christopher Liang, Jogeshwar Mukherjee

Open access · goldAbstract read
In one paragraph

Article in Frontiers in neuroscience, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
1.5field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 19 citations in OpenAlex.

  1. Increased Binding of [Synapse (New York, N.Y.) · 2026
    Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Abnormal [Synapse (New York, N.Y.) · 2023
    Article
  11. Article
  12. Development of [Molecules (Basel, Switzerland) · 2023
    Article
  13. Article
  14. [Molecules (Basel, Switzerland) · 2022
    Article
  15. [Molecules (Basel, Switzerland) · 2021
    Article
  16. Development and evaluation of [Bioorganic & medicinal chemistry letters · 2021
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Rommani MondalPreclinical Imaging, Department of Radiological Sciences, University of California, Irvine, Irvine, CA, United States.
Anthony-David Tawatao CampoyPreclinical Imaging, Department of Radiological Sciences, University of California, Irvine, Irvine, CA, United States.
Christopher LiangPreclinical Imaging, Department of Radiological Sciences, University of California, Irvine, Irvine, CA, United States.
Jogeshwar MukherjeePreclinical Imaging, Department of Radiological Sciences, University of California, Irvine, Irvine, CA, United States.
University of California, Irvine · US

Funding

NIA NIH HHS RF1 AG029479
6 · The paper itself

Abstract

Transgenic mice line M83 that express the A53T mutant α-synuclein protein at six times the level of endogenous mice α-synuclein are a model of α-synucleinopathy found in Parkinson's disease (PD). This Hualpha-Syn (A53T) PD model is useful in assessing non-motor deficits at earlier stages of onset of PD. We report findings on metabolic changes using [

Indexed as

[18F]FDG PET/CTbrainHualpha-Syn A53T micehypometabolismlimb muscleParkinson’s diseasespinal cordα-synuclein

Identifiers

PMID34211366
PMCPMC8239288
OpenAlexW3172503575

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.